ClinicalTrials.gg
RecruitingNCT04079179NACHO-COBIUpdated Oct 26, 2026

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

A Phase 2 interventional study of Cobimetinib in Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma and Erdheim-Chester Disease, sponsored by Carl Allen. Recruiting at 12 sites in United States. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Carl Allen · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Apr 2021; still recruiting 5 years 7 months later.
Updated Oct 26, 2026Primary completion movedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Histiocytosis, Langerhans-Cell with a site in United States — 8 open to participants now, 25 under way, 2 of them phase 3. Histiocytosis, Langerhans-Cell · United States.

Planned enrollment
8th of 40
90 · median 21
Started
2021
with 2 others
Phase 2
27 of 47
4 open now
Primary completion
2028-01
later than 18 of 24 live
Registered
37th of 47
by date
Lead sponsor
1 of 47
Carl Allen

Among the 47 studies in Histiocytosis, Langerhans-Cell with a site in United States, this one is the 8th largest by planned enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2021, is one of 27 in phase 2, reaches primary completion later than 18 of the 24 other live ones, and was the 37th registered.

Histiocytosis, Langerhans-Cell

81 studies on the registry are indexed under Histiocytosis, Langerhans-Cell; 23 are open to participants now.

Browse Histiocytosis, Langerhans-Cell studies →

Open to participants now

8 of the 47 studies in Histiocytosis, Langerhans-Cell with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Histiocytosis, Langerhans-Cell studies recruiting now, 8 (42%) set no upper age limit and 10 (53%) stop at 75 or younger; 13 take children under 18; 1 takes healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Histiocytosis, Langerhans-Cell with a site in United States, or all of them as a file.
02

Study summary

This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.

Read the detailed description

Histiocytic disorders are diseases caused by misfunctioning or buildup of particular immune cells called histiocytes. Many histiocytic disorders (LCH, juvenile xanthogranuloma (JXG), Erdheim-Chester disease (ECD), and Rosai-Dorfman Disease (RDD)) arises from blood cells that receive incorrect growth signals. These incorrect signals are caused by changes in genes (mutations) that lead to tissue damage (lesions) which causes disease. Some patients with LCH can develop neurodegeneration (LCH-ND) which is damage to neurons that results in reduced brain function, from LCH cells that go to the brain and activate inflammation. LCH arises from blood cells that receive incorrect growth signals. These incorrect signals are caused by mutations (changes in genes). The LCH blood cells can create changes in the structure of almost any organ, and can cause damage to normal organ function.

The purpose of this research study is to learn whether cobimetinib is safe and effective in subjects diagnosed with LCH, LCH-ND, RDD, JXG and ECD which may have a specific mutation called BRAF-V600E. In healthy cells, certain proteins (called BRAF and MEK) are thought to help control normal cell growth. BRAF-V600E is a specific change in a gene that may cause cancer cells to grow and spread by sending constant signals to the MEK protein. Cobimetinib is designed to attach to and block the activity of MEK.

03

Conditions studied

  • Langerhan's Cell Histiocytosis
  • Juvenile Xanthogranuloma
  • Erdheim-Chester Disease
  • Rosai Dorfman Disease
  • Neuro-Degenerative Disease
  • Histiocytic Sarcoma
  • Histiocytic Disorders, Malignant

Keywords

  • Cobimetinib
  • Langerhans Cell Histiocytosis (LCH)
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

INCLUSION CRITERIA:

Age at study entry

  • For Group 1: Participant must be at least 6 months of age and less than 21 years of age at the time of enrollment
  • For Group 2: Participant may be at least 6 months of age at the time of enrollment
  • For Group 3: Participant must be at least 6 months of age and less than 21 years of age at the time of enrollment
  • For Group 4: Participant must be 21 years of age or older at the time of enrollment
  • Participant must be able to take an enteral dose and formulation of medication. Study medication is only available as an oral suspension or tablet which may be taken by mouth or other enteral route such as nasogastric or gastric tube.

As of 27Feb2026, due to suspension no longer being available, subject must be able to swallow tablets.

- proven LCH -AND

  • Failure of at least front-line therapy for LCH with evaluable disease. -OR
  • Diagnosis of LCH-associated neurodegenerative disease with radiologic or clinical progression within the past 3 months. -OR
  • Biopsy proven JXG, ECD, RDD, histiocytic sarcoma, or other histiocytic lesion (newly diagnosed or disease) with evaluable active disease.

Performance Level:

- ≥ 50% for patients > 16 years of age and Lansky ≥ 50% for patients ≤ 16 years of age.

Adequate Hematologic Function Defined as:

  • ≥ 0.75 x 10\^9/L (unsupported/without growth factor stimulant)
  • count ≥ 75 x 10\^9/L (unsupported/without transfusion within the past 7 days).
  • Patients with marrow disease must have platelet count of >/= 75 x 10\^9/L (transfusion support allowed) and must not be refractory to platelet transfusions.
  • ≥ 8 g/dL (unsupported/without transfusion within the past 7 days)
  • Patients with marrow disease must have hemoglobin ≥ 8 g/dL (transfusion support allowed).

Adequate Renal Function Defined as:

- Calculated (or radioisotope ) ≥ 70 mL/min/1.73m\^2 or serum creatinine based on age/gender as follows:

Maximum Serum Creatinine (mg/dL) Age 2 to \< 6 years: Male 0.8 mg/dL, Female 0.8; 6 to \< 10 years: Male 1 mg/dL,Female 1; 10 to \< 13 years: Male 1.2 mg/dL; Female 1.2; 13 to \< 16 years: Male 1.5 mg/dL ; Female 1.4; ≥ 16 years: Male 1.7 mg/dL; Female 1.4;

Adequate Liver Function Defined as:

  • (sum of conjugated + unconjugated) ≤ 1.5 x (ULN) for age
  • and ALT ≤ 3x ULN (≤ 5 x ULN for participants with liver involvement)
  • Serum albumin ≥ 2 g/dL.

For patients with liver disease caused by histiocytic disorder:

  • Patients may be enrolled with abnormal bilirubin, AST, ALT and albumin with documentation of histiocytic liver disease.

Adequate Cardiac Function Defined as:

- Fractional shortening (FS) of ≥ 30% or of ≥ 50% by echocardiogram at baseline, as determined by echocardiography or multigated acquisition scan (MUGA) within 28 days prior to enrollment. Depending on institutional standard, either FS or LVEF is adequate for enrollment if only one value is measured; if both values are measured, then both values must meet criteria above

Pregnancy/

  • Female patients of require a negative urine or serum pregnancy test for eligibility and again at database registration, if more than 2 weeks has elapsed.
  • Female patients of childbearing potential must agree to follow the contraceptive requirements using two forms of effective contraceptive methods for the duration of the study treatment. Male patients with sexual partners who are pregnant or who could become pregnant (i.e., women of child-bearing potential) must agree to use two forms of effective methods of contraception (one of which must be a barrier method) during the treatment period and for at least 3 months after the last dose of the study drug to avoid pregnancy and/or potential adverse effects on a developing embryo. Agreement to true abstinence (not periodic abstinence or withdrawal method) is an acceptable method of birth control.

EXCLUSION CRITERIA:

- Prior and Concomitant Use of Drugs with inducing/inhibiting activity: Patient taking strong inducers or inhibitors of CYP3A4 within 14 days prior to study enrollment, including but not limited to the following: erythromycin, clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St. John's wort.

  • Prior Therapy Restrictions Completion of previous chemotherapy, immunotherapy, radiotherapy, or targeted therapy for LCH (or other histiocytic disorder) at least 28 days (except where specified below) prior to study enrollment, with resolution of all associated toxicity to ≤ Grade 1 prior to study enrollment (exception for alopecia and ototoxicity which do not need to be resolved ≤ Grade 1). Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment. If after the required timeframe, the laboratory eligibility criteria are met, the patient is considered to have recovered adequately. See below for specific consideration of prednisone and prior to enrollment.

    • Radiation therapy within the 14 days prior to enrollment.
    • Any prior treatment with Cobimetinib.
    • Treatment with a long-acting hematopoietic growth factor within 14 days prior to initiation of study drug or a short-acting hematopoietic growth factor within 7 days prior to enrollment.
    • Treatment with hormonal therapy (except hormone replacement therapy or oral contraceptives), immunotherapy, biologic therapy, therapy, or herbal cancer therapy within 28 days or \< 5 half-lives, whichever is longer, prior to study enrollment.
    • Treatment with high-dose chemotherapy and stem-cell rescue ( stem cell transplant) or allogeneic stem cell transplant within 90 days prior to enrollment. Anti- agents post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial.
    • For patients with brain tumors (intracranial masses), use of anticoagulants within 7 days prior to enrollment.
    • Corticosteroid therapy less than or equal to 0.5 mg/kg/day averaged during the 28 days prior to study enrollment is permissible. Patients receiving corticosteroids must be on a stable or decreasing dose for 14 days prior to enrollment and discontinue once study treatment has started.
    • Patient has received treatment with investigational therapy within 4 weeks prior to initiation of study drug.
    • Patients taking anticoagulants or have a pre-existing bleeding disorder unrelated to histiocytic disease.
  • Exclusions for other illness

    • Other active or history of secondary malignancy.
    • Refractory nausea and vomiting, malabsorption, external biliary shunt
    • Infection: Patients who have a known active infection (excluding documented fungal infection of the nail beds) within 28 days prior to enrollment that has not completely resolved.
    • Major surgical procedure or significant traumatic injury within 28 days prior to enrollment, or anticipation of need for major surgical procedure during the course of the study. Placement of a vascular access device or minor surgery is permitted within fourteen (14) days prior to study enrollment (provided that the wound has healed).
    • History of significant bowel resection that would preclude adequate absorption or other significant malabsorptive disease.
    • History of pneumonitis.
    • Ophthalmologic considerations: Patients with known significant ophthalmologic conditions or known risk factors for retinal vein occlusion are not eligible. Specifically, patients with a history of retinal vein occlusion (RVO), retinal detachment, retinal pathology on ophthalmologic exam, retinopathy of prematurity, central serous chorioretinopathy (CSSCR), neovascular retinopathy, intraocular pressure > 21 mmHg, and predisposing factors to RVO (e.g., uncontrolled hypertension, diabetes, or hyperlipidemia, coagulopathy) will be excluded. Patients with longstanding and stable ophthalmologic findings secondary to existing conditions are eligible with appropriate written documentation and approval from Study Chair.
    • History of solid organ transplantation: Patients who have received a prior solid organ transplantation are not eligible.
    • Any other disease, metabolic or psychological dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that in the opinion of the investigator contraindicates use of an investigational drug or places the patient at unacceptable risk from treatment complications.
  • History of cardiac dysfunction, including the following:

    • Clinically significant cardiac arrhythmias including brady-arrhythmias and/or patients who require anti-arrhythmic therapy (with the exception of beta blockers or digoxin). Patients with controlled atrial fibrillation are not excluded.
    • Unstable arrhythmia
    • Unstable angina, or new-onset angina within 3 months prior to initiation of study treatment
    • Symptomatic congestive heart failure, defined as Class II or higher
    • Myocardial infarction within 3 months prior to initiation of study treatment
  • Known chronic (HIV).
  • History of Grade ≥ 2 CNS hemorrhage or history of any CNS hemorrhage within 28 days of enrollment.
  • Female patients who are pregnant or lactating. Pregnant or lactating women will not be entered on this study because there is no available information regarding human fetal or teratogenic toxicities.
  • As of 27Feb2026, children less than 20 kg, due to discontinuation of suspension formulation.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Patients < 21 years with recurrent LCH (Grp1)

    Children (≥ 6 months) and young adults (\<21 years) with recurrent active LCH lesions (may also have LCH-ND).

    Drug: Cobimetinib

  • Experimental
    Patients of any age with LCH-ND (Grp2)

    Patients of any age (≥ 6 months) with progressive LCH Neurodegenerative Disease (LCH-ND) without other sites of active LCH.

    Drug: Cobimetinib

  • Experimental
    Patients <21 years with other histiocytic disorders (Grp3)

    Newly diagnosed or relapsed/refractory children (≥ 6 months) and young adults (\<21 years) with other histiocytic disorders including juvenile xanthogranuloma, Erdheim-Chester disease, histiocytic sarcoma and Rosai-Dorfman disease.

    Drug: Cobimetinib

  • Experimental
    Patients ≥ 21 years with LCH/histiocytic disorders (Grp4)

    Adults (≥21 years) with LCH or other histiocytic disorder with recurrent active lesions (may also have LCH-ND).

    Drug: Cobimetinib

Interventions

  • Cobimetinib will be administered at a maximal dose of 60 mg daily for patients \<18 years old and a flat dose of 40 mg daily for patients ≥18 years for 21 days on, then 7 days off, in a 28-day treatment cycle for a total of 12 cycles (approximately 12 months).

    Also known as: COTELLIC, RO5514041

06

What researchers measure

Primary outcomes

  1. Overall Response Rates using modified RECiST criteria

    Proportion of participants with (complete response, partial response, stable disease, progressive disease) by 1 year of therapy with Cobimetinib. It is assumed that at each protocol-specified timepoint, a response assessment occurs. Status calculation will occur at each timepoint for patients who have measurable disease at baseline per the criteria defined in the protocol.

    Time frame: 12 months

Secondary outcomes

  1. Progression Free Survival

    Progression Free Survival defined as the length of time during and after the treatment of a disease, that a patient lives with the disease but it does not get worse.

    Time frame: 12 months

  2. Nature and Severity of Adverse Events

    Assessment of the nature and severity of adverse events in patients treated with Cobimetinib for histiocytic disorders.

    Time frame: 12 months

Other outcomes

  1. Response assessment (Modified RECIST) of histiocytic lesions with specific mutations

    Response assessment using modified RECIST criteria for target lesions with specific mutations (e.g. BRAF-V600E) . Best response rate by 1 year of therapy.

    Time frame: 12 months

07

Study locations

10 of 12 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Jan 2028, 81 months after the start.

Of 32 phase 2 interventional studies under Histiocytosis, Langerhans-Cell, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 85. This study's planned 81 months is above that.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2025 → Jan 2028, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2019
First posted
Sep 6, 2019
StartActual
Apr 19, 2021
Primary completionEst.
Jan 2028was Dec 2025
CompletionEst.
Dec 2029
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2025→Jan 2028
Oct 26, 2026
Eligibility
1 criterion edited, 2 added
What changed in the criteria
  • AddedAs of 27Feb2026, due to suspension no longer being available, subject must be able to swallow tablets.
  • Edited-Biopsy proven LCH -AND
  • AddedAs of 27Feb2026, children less than 20 kg, due to discontinuation of suspension formulation.
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Primary completion Dec 2025→Jan 2028
    Eligibility 1 criterion edited, 2 added
    What changed in the criteria
    • AddedAs of 27Feb2026, due to suspension no longer being available, subject must be able to swallow tablets.
    • Edited-Biopsy proven LCH -AND
    • AddedAs of 27Feb2026, children less than 20 kg, due to discontinuation of suspension formulation.
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04079179
Lead sponsor
Carl Allen
Collaborators
Baylor College of Medicine, North American Consortium for Histiocytosis, Genentech, Inc.
Responsible party
Carl Allen (Associate Professor, Baylor College of Medicine) — Sponsor-investigator
First posted
Sep 6, 2019
Start date
Apr 19, 2021
Primary completion
Jan 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 26, 2026

Study contacts

Carl E Allen, MD, PhD
Contact
ceallen@texaschildrens.org
832-822-4242
Olive Eckstein, MD
Contact
Eckstein@bcm.edu
832-822-4242
Carl E Allen, MD, PhD
study chair · Baylor College of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cobimetinib

Start the discussion